{"schema_version":"secwatch.filing_event.v1","accession":"0001728117-23-000009","form_type":"8-K","ticker":"GOSS","cik":"0001728117","company_name":"Gossamer Bio, Inc.","filed_at":"2023-03-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.332719+00:00","generated_at":"2026-06-17T23:37:46.627688+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Gossamer Bio pauses GB5121 enrollment, advances seralutinib Phase 3","bullets":["Seralutinib Phase 3 in PAH to start H2 2023; dose 90 mg BID, primary endpoint 6-minute walk distance.","TORREY open-label extension topline data expected mid-2023.","GB5121 Phase 1b/2 enrollment paused due to benefit/risk profile and resource prioritization toward seralutinib.","Cash of $255.7M at Dec 31, 2022; expected to fund operations into H2 2024.","Full-year 2022 net loss $229.4M ($2.71/share), vs $234.0M ($3.13/share) in 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001728117-23-000009","json":"https://secwatch.observer/filing/0001728117-23-000009.json","markdown":"https://secwatch.observer/filing/0001728117-23-000009.md","text":"https://secwatch.observer/filing/0001728117-23-000009.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728117/000172811723000009/0001728117-23-000009-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728117/000172811723000009/goss-20230317.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T23:37:46.627688+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4065993e7839a291e4616fa35c13c3352aa8971b","claim":"Gossamer Bio, Inc. reported the full year ended December 31, 2022 results: net income Net loss for the full year ended December 31, 2022, was $229.4 million, EPS $2.71 per share.","evidence_excerpt":"Net loss for the full year ended December 31, 2022, was $229.4 million, or $2.71 per share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1728117/000172811723000009/0001728117-23-000009-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2022"},{"label":"Net income","value":"Net loss for the full year ended December 31, 2022, was $229.4 million"},{"label":"EPS","value":"$2.71 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"5a7f76295076e831e5fbb1a0d6c443d81ee13a03","claim":"Gossamer Bio, Inc. reported the three months ended December 31, 2022 results: net income Net loss for the three months ended December 31, 2022, was $55.8 million, EPS $0.59 per share.","evidence_excerpt":"Net loss for the three months ended December 31, 2022, was $55.8 million, or $0.59 per share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1728117/000172811723000009/0001728117-23-000009-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended December 31, 2022"},{"label":"Net income","value":"Net loss for the three months ended December 31, 2022, was $55.8 million"},{"label":"EPS","value":"$0.59 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}